HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Methylglyoxal and methylglyoxal-arginine adducts do not directly inhibit endothelial nitric oxide synthase.

Abstract
Increased formation of the reactive dicarbonyl compound methylglyoxal (MGO) and MGO-derived advanced glycation end products (AGEs) seems to be implicated in endothelial dysfunction and the development of diabetic vascular complications. MGO reacts with arginine residues in proteins to generate the major glycated adducts 5-hydro-5-methylimidazolone (MG-H1) and argpyrimidine (AP). We investigated whether the free forms of these adducts contribute to vascular cell dysfunction by inhibition of endothelial nitric oxide synthase (eNOS). MG-H1 and AP were synthesized and purified by reversed-phase chromatography, and the conversion of labeled L-arginine to L-citrulline was used to monitor eNOS activity. In contrast to the endogenous eNOS inhibitor asymmetric dimethylarginine (half maximal inhibitory concentration, approximately 5 micromol/L), pathophysiological concentrations of MGO and MG-H1 and AP did not inhibit eNOS activity. Although MGO-derived AGEs are implicated in the development of diabetic vascular complications, this study indicates that this is not mediated via direct inhibition of eNOS activity.
AuthorsOlaf Brouwers, Tom Teerlink, Jan van Bezu, Rob Barto, Coen D A Stehouwer, Casper G Schalkwijk
JournalAnnals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 1126 Pg. 231-4 (Apr 2008) ISSN: 0077-8923 [Print] United States
PMID18079474 (Publication Type: Journal Article)
Chemical References
  • Anthracenes
  • Enzyme Inhibitors
  • N,N-dimethylarginine
  • Pyruvaldehyde
  • Arginine
  • Nitric Oxide Synthase Type III
  • Propane
Topics
  • Anthracenes (pharmacology)
  • Arginine (analogs & derivatives, pharmacology)
  • Endothelium, Vascular (enzymology)
  • Enzyme Inhibitors (pharmacology)
  • Humans
  • Nitric Oxide Synthase Type III (antagonists & inhibitors)
  • Propane (analogs & derivatives, pharmacology)
  • Pyruvaldehyde (analogs & derivatives, pharmacology)
  • Umbilical Veins (enzymology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: